Overview

Gender

male

David Davidson, M.D., has served as our chief medical officer since February 2012. Prior to joining us, Dave served as a senior medical director at Genzyme Corporation, or Genzyme, where he led clinical research for programs in Phases I through IV across a wide range of therapeutic areas for more than a decade. Most recently, Dave was the medical leader for Genzyme’s gene therapy and Pompe disease enzyme replacement therapy programs. In addition to Dave’s translational medicine experience, he has also worked on a number of commercial products, including Fabrazyme and Myozyme/Lumizyme, and was integral in crafting the new drug application that resulted in the approval of Welchol. Prior to Genzyme, Dave was a medical director at GelTex Pharmaceuticals Inc., he completed clinical and research fellowships in infectious diseases at the Harvard Longwood Combined Infectious Diseases Program, and received his B.A. from Columbia University and his M.D. from New York University School of Medicine. In addition, he completed an internal medicine internship, residency training and an endocrinology research fellowship at the University of Chicago Hospitals.